An endogenous 28-amino acid thymic peptide researched for restoring immune competence, enhancing T-cell and natural killer cell activity, and modulating Toll-like receptors.
~2 hours (rapid systemic distribution)
Toll-Like Receptor 9 (TLR9)
C129H215N33O55
Administered via subcutaneous injection twice or three times weekly.
Small or observational human data; warrants clinical caution.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for Thymosin Alpha-1: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C129H215N33O55
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
Thymosin Alpha-1 (Tα1) was first isolated from thymus tissue fraction 5 by Dr. Allan Goldstein in 1977. Marketed internationally under the name Zadaxin, it is approved in over 30 countries as an immune adjuvant for chronic hepatitis B and C, and investigated in severe viral infections and oncology protocols. It exhibits potent pleiotropic immunomodulatory actions without inducing excessive cytokine release syndrome.
Signals through Toll-like receptors (TLR9 and TLR2) on myeloid and plasmacytoid dendritic cells, stimulating maturation of naive T cells into Th1 CD4+ and CD8+ cytotoxic lymphocytes, increasing interferon-gamma (IFN-γ) and interleukin-2 (IL-2).
Peer-reviewed publications, clinical trials, and preclinical research investigating Thymosin Alpha-1.
Multicenter randomized trial demonstrating that thymosin alpha-1 immunotherapy reduces 28-day all-cause mortality from 35.0% to 26.0% in patients with severe sepsis and immune paralysis.
Documented literature dosing intervals and published clinical trial protocols.
Biological delivery routes and standardized laboratory reconstitution principles.
Administered via subcutaneous injection twice or three times weekly.
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolCompiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.
